Поражение кожных покровов при трансплантации гемопоэтических стволовых клеток. Обзор литературы

Поражение кожи после трансплантации гемопоэтических стволовых клеток (ТГСК) встречается достаточно часто и представляет собой важную диагностическую и терапевтическую проблему. Наиболее значимыми причинами поражений кожи при ТГСК являются медикаментозная токсичность, инфекционные поражения, проявления кожной формы острой и хронической реакции «трансплантат против хозяина». Каждое из осложнений может проявляться в различной степени, а также сочетаться с другими, оказывая значимое отрицательное влияние на состояние пациента, в тяжелых случаях представляя угрозу для жизни больного. В статье обобщены данные об этиологии, особенностях патогенеза, клинических формах, основных методах диагностики и терапии наиболее часто встречающихся кожных осложнений при ТГСК.

1. Paun O., Phillips T., Fu P., Novoa R.A., Honda K.S., Lu K.Q., Lazarus H.M. Cutaneous complications in hematopoietic cell transplant recipients: impact of biopsy on patient management. Biol Blood Marrow Transplant 2013; 19 (8): 1204–9. DOI: 10.1016/j.bbmt.2013.05.006

2. Filipovich A.H., Weisdorf D., Pavletic S., Socie G., Wingard J.R., Lee S.J., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versushost disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11 (12): 945–56. doi: 10.1016/j.bbmt.2005.09.004

3. Carreras E., Dufour C., Mohty M., Kröger N. (eds.). The EBMT Handbook. Hematopoietic Stem Cell Transplantation and Cellular Therapies. This Springer; 2019. 688 р.

4. Zeiser R., Penack O., Holler E., Idzko M. Danger signals activating innate immunity in graft-versus-host disease. J Mol Med (Berl) 2011; 89 (9): 833–45. DOI: 10.1007/s00109-011-0767-x

5. Sung A.D., Chao N.J. Acute graft-versushost disease: are we close to bringing the bench to the bedside? Best Pract Res Clin Haematol 2013; 26 (3): 285–92. DOI: 10.1016/j.beha.2013.10.009

6. Pidala J., Sigdel T.K., Wang A., Hsieh S., Inamoto Y., Martin P.J., et al. A combined biomarker and clinical panel for chronic graft versus host disease diagnosis. J Pathol Clin Res 2017; 3 (1): 3–16. DOI: 10.1002/cjp2.58.eCollection 2017Jan

7. Saliba R.M., de Lima M., Giralt S., Andersson B., Khouri I.F., Hosing C., et al. Hyperacute GVHD: risk factors, outcomes, and clinical implications. Blood 2007; 109 (7):2751–8. DOI: 10.1182/blood-2006-07-034348

8. Румянцев А.Г., Масчан А.А., Балашов Д.Н., Скворцова Ю.В. Федеральные клинические рекомендации по лечению хронической реакции «трансплантат против хозяина» после трансплантации гемопоэтических стволовых клеток у детей. М.; 2015. (Электронный ресурс). URL: http://nodgo.org/sites/default/files/29(Г)хртгскР.pdf.

9. Min C.-K. The pathophysiology of chronic graft-versus-host disease: the unveiling of an enigma. Korean J Hematol 2011; 46(2): 80. DOI:10.5045/kjh.2011.46.2.80

10. Shulman H.M., Kleiner D., Lee S.J., Morton T., Pavletic S.Z., Farmer E., et al. Histopathologic diagnosis of chronic graftversus- host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant 2006; 12 (1): 31–47. DOI: 10.1016/j.bbmt.2005.10.023

11. Jaffee B.D., Claman H.N. Chronic graftversus- host disease (GvHD) as a model for scleroderma. Cellular Immunology 1983; 77 (1): 1–12. DOI: 10.1016/0008-8749(83)90001-1

12. Murata T., Husain S.R., Mohri H., Puri R.K. Two different IL-13 receptor chains are expressed in normal human skin fibroblasts, and IL-4 and IL-13 mediate signal transduction through a common pathway. Int Immunol 1998; 10 (8): 1103–10. DOI: 10.1093/intimm/10.8.1103

13. Atamas S.P., White B. The role of chemokines in the pathogenesis of scleroderma. Curr Opin Rheumatol 2003; 15 (6): 772–7. DOI: 10.1097/00002281-200311000-00015

14. Jagasia M.H., Greinix H.T., Arora M., Williams K.M., Wolff D., Cowen E.W., et al. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2015; 21 (3): 389–401.e1. DOI: 10.1016/j.bbmt.2014.12.001

15. Jang S., Kim I.S., Youn S.W. Chronic graftversus- host disease mimicking psoriasis in a patient with hemophagocytic lymphohistiocytosis. Ann Dermatol 2016; 28 (1): 90–3. DOI: 10.5021/ad.2016.28.1.90

16. Ceovic´ R., Desnica L., Pulanic´ D., Serventi Seiwerth R., Ilic´ I., Grce M., et al. High frequency of cutaneous manifestations including vitiligo and alopecia areata in a prospective cohort of patients with chronic graft-vs-host disease. Croat Med J 2016; 57 (3): 229–38. DOI: 10.3325/cmj.2016.57.229

17. Kim S.J., Choi J.M., Kim J.E., Cho B.K., Kim D.W., Park H.J. Clinicopathologic characteristics of cutaneous graft-versus- host disease: a retrospective study in Korean patients. Int J Dermatol 2010; 49 (12): 1386–92. DOI: 10.1111/j.1365-4632.2010.04552.x

18. Manalo I.F., Miller I.A., Davies L.S. More immune dysregulation: sarcoidosis and chronic graft-versus-host disease after allogeneic stem cell transplant. JAAD Case Rep 2016; 2 (2): 138–40. DOI: 10.1016/j.jdcr.2016.01.008

19. Paczesny S., Braun T.M., Levine J.E., Hogan J., Crawford J., Coffing B., et al. Elafin is a biomarker of graft versus host disease of the skin. Sci Transl Med 2010; 2 (13): 1–19. DOI: 10.1126/scitranslmed.3000406

20. Levine J.E., Braun T.M., Harris A.C., Holler E., Taylor A., Miller H., et al. A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study. Lancet Haematol 2015; 2 (1): е21–9. DOI: 10.1016/S2352-3026(14)00035-0

21. Penack O., Marchetti M., Ruutu T., Aljurf M., Bacigalupo A., Bonifazi F., et al. Prophylaxis and management of graft versus host disease after stemcell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol 2020; 7 (2): e157–67. DOI: 10.1016/S2352-3026(19)30256-X.

22. Bolognia J.L., Cooper D.L., Glusac E.J. Toxic erythema of chemotherapy: a useful clinical term. J Am Acad Dermatol 2008; 59 (3): 524–9. DOI: 10.1016/j.jaad.2008.05.018.

23. Horn T.D., Beveridge R.A., Egorin M.J., Abeloff M.D., Hood A.F. Observations and proposed mechanism of N,N9,N99-triethyl-enethiophosphoramide (thiotepa)-induced hyperpigmenta-tion. Arch Dermatol 1989; 125 (4): 524–7.

24. Mays S.R., Kunishige J.H., Truong E., Kontoyiannis D.P., Hymes S.R. Approach to the morbilliform eruption in the hematopoietic transplant patient. Semin Cutan Med Surg 2007; 26 (3): 155–62. DOI: 10.1016/j.sder.2007.09.004

25. Betts B.C., Young J.A., Ustun C., Ustun C., Cao Q., Weisdorf D.J. Human herpesvirus 6 infection after hematopoietic cell transplantation: is routine surveillance necessary? Biol Blood Marrow Transplant 2011; 17 (10): 1562–8. DOI: 10.1016/j.bbmt.2011.04.004

26. Dignan F.L., Clark A., Amrolia P., Cornish J., Jackson G., Mahendra P., et al. Diagnosis and management of acute graftversus- host disease. Br J Haematol 2012; 158 (1): 30–45. DOI: 10.1111/j.1365-2141.2012.09129.x

27. Rosman I.S., Lloyd B.M., Hayashi R.J., Bayliss S.J. Cutaneous effects of thiotepa in pediatric patients receiving high-dose chemotherapy with autologous stem cell transplantation. J Am Acad Dermatol 2008; 58 (4): 575–8. DOI:10.1016/j.jaad.2007.12.037

28. Balsat M., Pillet S., Tavernier E., Cacheux V., Escuret V., Moluçon-Chabrot C., et al. Human Herpesvirus 6 Infection after Autologous Stem Cell Transplantation: A Multicenter Prospective Study in Adult Patients. J Infect 2019; 79 (1): 36–42. DOI: 10.1016/j.jinf.2019.05.001

29. Miura T., Kikuchi N., Ohtsuka M., Yamamoto T. Varicella in a patient with drug-induced hypersensitivity syndrome developed after autologous peripheral stem cell transplantation. Int J Dermatol 2018; 57 (9): e71–e73. DOI: 10.1111/ijd.14091